Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Joong-Won | - |
dc.contributor.author | Finn, Richard S. | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.contributor.author | Karwal, Mark | - |
dc.contributor.author | Li, Ruby K. | - |
dc.contributor.author | Ismail, Fuad | - |
dc.contributor.author | Thomas, Melanie | - |
dc.contributor.author | Harris, Rosemarie | - |
dc.contributor.author | Baudelet, Christine | - |
dc.contributor.author | Walters, Ian | - |
dc.contributor.author | Raoul, Jean-Luc | - |
dc.date.accessioned | 2021-09-07T13:25:37Z | - |
dc.date.available | 2021-09-07T13:25:37Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-04-01 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112677 | - |
dc.description.abstract | Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has demonstrated encouraging antitumor activity in preclinical and phase I studies. We performed a phase II open-label study of brivanib as first-line therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Experimental Design: Brivanib was administered orally at a dose of 800 mg once daily. The primary objective was 6-month progression-free survival, progression-free survival rate; secondary objectives were tumor response rate, time to response, duration of response, median progression-free survival, median overall survival, disease control rate (complete response, partial response, or stable disease >= 42 days), and safety and tolerability. Results: Between March 2007 and May 2009, 55 patients were treated and were evaluable for response. Patients were assessed using modified World Health Organization (mWHO) criteria. According to mWHO criteria and as assessed by Independent Response Review Committee, the six-month progression-free survival rate (95% CI) was 18.2% (9.1%-30.9%). Median progression-free survival (95% CI) was 2.7 months (1.4-3.0). One patient achieved a complete response and three achieved a partial response. Twenty-two had stable disease. Median overall survival (95% CI) was 10 (6.8-15.2) months. Brivanib was generally well tolerated; the most common adverse events included fatigue, hypertension, and diarrhea. Conclusion: Brivanib as first-line therapy demonstrates promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC. Clin Cancer Res; 17(7); 1973-83. (C)2011 AACR. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.subject | FIBROBLAST-GROWTH-FACTOR | - |
dc.subject | SYSTEMIC CHEMOTHERAPY | - |
dc.subject | FACTOR RECEPTOR-2 | - |
dc.subject | DUAL INHIBITOR | - |
dc.subject | SORAFENIB | - |
dc.subject | METASTASIS | - |
dc.subject | TUMORS | - |
dc.subject | ANGIOGENESIS | - |
dc.subject | BMS-540215 | - |
dc.subject | MANAGEMENT | - |
dc.title | Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-10-2011 | - |
dc.identifier.scopusid | 2-s2.0-79953325932 | - |
dc.identifier.wosid | 000289054100035 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, v.17, no.7, pp.1973 - 1983 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.citation.title | CLINICAL CANCER RESEARCH | - |
dc.citation.volume | 17 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1973 | - |
dc.citation.endPage | 1983 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | FIBROBLAST-GROWTH-FACTOR | - |
dc.subject.keywordPlus | SYSTEMIC CHEMOTHERAPY | - |
dc.subject.keywordPlus | FACTOR RECEPTOR-2 | - |
dc.subject.keywordPlus | DUAL INHIBITOR | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | METASTASIS | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | BMS-540215 | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.